載入中
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
收盤時
US$8.60
−US$0.23 · -2.60%
盤後
US$8.61
+US$0.01 · +0.12%
10月12日 下午5:19 ET
盤中時間採用ET。市場資料可能有所延遲。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日內區間
目前US$8.60
52週區間
目前US$8.60
盤中時間採用ET。市場資料可能有所延遲。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日內區間
目前US$8.60
52週區間
目前US$8.60
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | 57.8萬 USD | 70.1萬 USD | 55.6萬 USD | 57.4萬 USD |
| 毛利 | −57.8萬 USD | −70.1萬 USD | −55.6萬 USD | −57.4萬 USD |
| 研究與開發 | 1.38億 USD | 6782.2萬 USD | 4911.9萬 USD | 2657萬 USD |
| 銷售、一般及管理費用 | 3073.4萬 USD | 1442.3萬 USD | 760.7萬 USD | 410.1萬 USD |
| 營業費用 | 1.69億 USD | 8224.5萬 USD | 5672.6萬 USD | 3067.1萬 USD |
| 利息收入 | 551.8萬 USD | 450.4萬 USD | 109.9萬 USD | 42.9萬 USD |
| 折舊和攤銷 | 57.8萬 USD | 70.1萬 USD | 55.6萬 USD | 57.4萬 USD |
| 營業利益 | −1.69億 USD | −8294.6萬 USD | −5728.2萬 USD | −3124.5萬 USD |
| 淨利 | −1.61億 USD | −7758萬 USD | −5570.9萬 USD | −3001.6萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$29.20
上漲空間 239.53%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
